IL1RL2 and psoriasis: Future approaches should therefore investigate to what extent IL-36 overactivation contributes to the development of psoriasis-associated comorbidities, and if anti-IL36R antibodies, alone or in combination with other anti-psoriatic drugs, are helpful in the treatment of these comorbidities.